Glen Eagle Advisors, LLC Glaukos Corp Transaction History

Glen Eagle Advisors, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$89.48 - $118.35 $14,764 - $19,527	-165 Closed	0 $0
Q2 2018 Aug 13, 2024	SELL	$27.62 - $44.51 $4,557 - $7,344	-165 Closed	0 $0
Q1 2018 Aug 14, 2024	BUY	$26.05 - $34.5 $4,298 - $5,692	165 New	165 $5.09 Million
Q4 2017 Aug 13, 2024	SELL	$24.5 - $36.01 $2,327 - $3,420	-95 Reduced 36.54%	165 $4.23 Million
Q3 2017 Aug 13, 2024	BUY	$31.26 - $42.03 $8,127 - $10,927	260 New	260 $8.58 Million
Q1 2017 Aug 12, 2024	BUY	N/A	100	100 $5.13 Million

342

47.1M

132K

188K

Ticker GKOS
Exchange NYSE
Sector Healthcare
Industry Medical Devices
Shares Outstandng 47,596,900
Market Cap $6.8B
Description
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-...

Get notified when there are updates to the investment portfolio of Glen Eagle Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Glen Eagle Advisors, LLC with notifications on news.